Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Eli Lilly CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in ...

Eli Lilly is raising the UK price of its obesity drug by 170%. Additionally, Unite Group buys rival student landlord Empiric ...

Maker of popular Mounjaro treatment seeks to address White House concerns over higher medicine costs for Americans ...

Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.